In 2016, the H3R antagonist/inverse agonist pitolisant (Wakix®) was approved as a treatment for narcolepsy, and, in 2019, as Ozawade® for excessive daytime sleepiness in individuals with sleep apnea [10,11,12], as well as several other H3R antagonists/inverse agonists in (pre-)clinical trials [8]. This evidence concerns the gene HRH3 and narcolepsy.